Lara M. Simpson, PhD

Faculty Associate
Coordinating Center for Clinical Trials
Department of Biostatistics and Data Science
University of Texas School of Public Health

OFFICE: **1200 Pressler St, W908**
713 500 9503 work
Lara.M.Simpson@uth.tmc.edu

EDUCATION:

Doctorate of Philosophy December 2006
University of Texas Health Science Center – Houston, School of Public Health
Epidemiology
Dissertation: The Combined Effect of Pravastatin and Aspirin on Clinical Cardiovascular Events

Master of Science December 1992
University of Texas Health Science Center – Houston, School of Public Health
Epidemiology
Thesis: Testicular Cancer in Texas, 1976-1985
Public Health Traineeship Award

Bachelor of Arts May 1990
University of Texas –Austin
Biology – High Honors, College of Natural Sciences
Minnie Stephens Piper Foundation Scholar, Dean's Scholar

PROFESSIONAL EXPERIENCE:
Coordinating Center for Clinical Trials (CCCT) at UTHSC-Houston, School of Public Health, 1990 – present.

Faculty Associate April, 2007 – Present

Co-Investigator
ALLHAT, 04/07 – Present (Post-trial Collaborations)
DCM-II, 05/20 – Present
ELPIS-II, 09/20 – Present
CHILD, 10/21 – Present
CCTRN, 01/07 – 02/2021
TWiTCH, 2010 – 2015

Direct data analyses (Stata, SAS) and the lead Clinical Trial Center/CCCT member on multiple *ALLHAT* manuscripts, including preparation of slides and posters for national and international meetings. Also work with programming for more complex analyses. Leader of Extended Mortality Follow-up through National Death Index (NDI) and Social Security Administration (SSA) in-trial, Extensions I, II, and III.; process involve including regulatory clearances, preparation and submission of file requests, search result review, database maintenance and integration. Member of the *ALLHAT* Heart Failure Validation Working Group. Continuing *ALLHAT* data resource for the Emerging Risk Factor Collaboration and Cholesterol Treatment Trialists' Collaboration. Participated in Executive, Endpoint, and Publications Subcommittees, as well as full Steering Committee activities. Collaborator on ALLHAT-related grant projects, including the Visit-to-Visit Variability in Blood Pressure Project, Improved Characteristics of Postural Blood Pressure Change in Older Adults, HEART: Adding Memory to Reason, Sustained Blood Pressure Control and Progression of Multimorbidity, Ten-year legacy effects of baseline blood pressure 'treatment naivety' in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Long-Term Benefits & Harms of Antihypertensive Drugs in the Elderly; all of which involve preparation of analysis files and manuscript preparation.

In two Phase IIB Randomized, Placebo-Controlled, Multicenter studies: Allogeneic hMSC Injection in Patients with Hypoplastic Left Heart Syndrome (ELPIS) and Phase IIB Multicenter Study of the Comparative Efficacy and Safety of Transendocardial Injection of MSC in Patients with Non-Ischemic Dilated Cardiomyopathy (DCM 11) trials, as well as the Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome: An Open Label Pilot Study (CHILD), function as the Safety Officer and oversee serious adverse event and clinical endpoint collection, review, MedDRA coding, assessment, monitoring, and reporting. Collaborate with pediatric and adult cardiologists for medical monitoring of serious events. Managed the DCC grant submission and successful resubmission process for ELPIS-II.

Develop and support serious adverse event and clinical endpoint collection, review, MedDRA coding, assessment, monitoring, and reporting (*TWiTCH, TIME, LateTIME, FOCUS, PACE, CONCERT, SENECA, ELPIS-II, DCM-II, CHILD*). Initiated *LateTIME* protocol design manuscript and assisted with development of final design manuscript, as well as performed baseline exploratory data analyses. Developed MedDRA coding capture, editing, and reporting for use in CCTRN Phase II protocols. Continue active MedDRA coding of event reports. Inaugural *CCTRN* activities included Phase II protocol development and deployment. Participate in Steering, Executive, and Regulatory Subcommittees. Continue in general Coordinating Center activities including developing, submitting, resubmitting, and obtaining grants.

Transition of *TWiTCH* protocol from private clinical research organization to CCCT began in summer of 2010. Participated in final-stage protocol review, development of TCD and other event monitoring, development of forms for electronic data capture systems, responsible for integration of MedDRA coding scheme into Coordinating Center systems, assisted with development and writing of study documentation necessary for protocol implementation. Participated in Operations, Executive, and Steering Committee activities. Safety Monitoring (review and reporting) of adverse and serious adverse events, and supervision of new neurologic event adjudication process. Trained and reviewed work of graduate and research assistants working with Safety Group. Participated in accelerated trial close-out, data analysis, and manuscript writing.

Managed *SHEP* Coordinating Center IRB reactivation and renewal for NDI Long Term Extended Mortality Follow-up through 30 years of follow-up, and NDI extended passive follow-up search. Collaboration with Robert Wood Johnson Medical School researchers.

Peer Reviewer

Trials 2010-Present
Clinical Trials: Journal of the Society for Clinical Trials 2008-Present

Guest Lecturer

Spring 2010 Topic: National Mortality Databases
Course: Methods in Clinical Epidemiology – Dr. Jan Risser

Assistant Project Manager ***CCTR Network,*** December 2006–04/07
Senior Research Assistant ***ALLHAT*** Trial, December 1999 – 04/07

Numerous *ALLHAT* activities described above as well as the following. Led preparation of *ALLHAT* data for the Emerging Risk Factor Collaboration. Supervised preparation of the Limited Access Dataset for National Heart, Lung, and Blood Institute, including creating the first comprehensive *ALLHAT* forms book. Also documented, reviewed, and tested SAS data files for drug companies participating in ALLHAT and for the FDA. Inaugural *ALLHAT* Slide Monitor after publication of final results, managed development of multiple slide sets among the Steering Committee members with a complicated review and finalization process imposed by the Committee.

General Coordinating Center activities included developing four Coordinating Center applications in response to NHLBI RFAs (Requests for Application), one of which was granted 12/06 (CCTRN).

During active patient follow-up in *ALLHAT* was the *ALLHAT Events Monitor*. Primarily responsible for day-to-day review of incoming event forms, documents, and corrections under the supervision of the *Medical Director*.

Trained and monitored graduate assistants hired to assist in event review. Distributed daily workloads in event reviewing, completed and corrected event inventory forms, completed correction requests, handled incoming correction requests and additional documentation submitted by the sites. Handled communications from clinical sites and regional coordinators regarding incomplete events. Reviewed reports for Endpoints Committee meetings, and took minutes for same, participated in Operations Subcommittee, helped design event questions for Investigator meetings (Grand Rounds Sessions), was assigned specific Regions for monitoring and problem solving, and attended Regional site visits

Assistant Project Manager ***CARE*** Trial, September 1991-November 1999
Senior Research Assistant - 1994-1999
Research Assistant II – 1991-1994

Oversaw and administered lipid management protocol phase of *CARE* (lipid-lowering agent trial), prepared endpoint data for investigator review, maintained review records, monitored medication status of study subjects, developed data collection tools for ancillary studies to *CARE*, and monitored the progress of the ancillary studies. Additional duties included data analyses, development and streamlining of internal programming (including subroutines) and external reports, handled data requests from ancillary investigators, and substituted for the *CARE* Safety Officer. Worked with trial investigators, project manager, another assistant project manager, programmers, data entry personnel, clinical center coordinators, and helped maintain working relationships between these different groups of employees. Trained and monitored the work of graduate assistants working with adverse event/endpoint records, and trained three Safety Officers (physicians) in data collection procedures for the *CARE* trial.

Graduate Research Assistant ***SAVE*** and ***CARE*** Trials, October 1990-September 1991
Helped develop a computerized inventory system of adverse event /endpoint forms and documents received, prepared endpoint data for investigator review for both trials, maintained adverse event/endpoint files, coded medication and adverse event/endpoint information on patient follow-up visit forms.

ONGOING RESEARCH SUPPORT:

1U24HL148316-01A1 (D. Lai, PI) $1,139,917.00 09/2020-08/2025
Allogeneic hMSC Injection in Patients with Hypoplastic Left Heart Syndrome (ELPIS)
UG3/UH3: National Heart, Lung and Blood Institute (NIH) (D. Lai, PI Data Coordinating Center)
Role: Co-Investigator

(D. Lai, PI) $3,933,322.00 05/2020-04/2025
A Phase IIB Multicenter Study of the Comparative Efficacy and Safety of Transendocardial Injection of MSC in Patients with Non-Ischemic Dilated Cardiomyopathy (DCM 11) (D. Lai, PI Data Coordinating Center)
Subcontract to University of Miami/DoD
Role: Co-Investigator

(D. Lai, PI) $562,245.00 10/2021 – *10*/2024
(no-cost extension in negotiation)
Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome: An Open Label Pilot Study (CHILD) (D. Lai, PI Data Coordinating Center)
Subcontract to Children's Healthcare of Atlanta (CHA)/University of Miami Medical Campus (UMMC)
Role: Co-Investigator

COMPLETED RESEARCH SUPPORT:

1R01AG058971 (X. Du, PI) $860,000.00 08/2018-03/2024
Ancillary to ALLHAT - "Long-Term Benefits & Harms of Antihypertensive Drugs in the Elderly in ALLHAT"
NIH R01
Role: Co-Investigator

2UM1HL087318, (B. Davis/L. Moyé, PI) $4,114,724.00 2012-2020
"Cardiovascular Cell Therapy Research Network (CCTRN)"
Role: Co-Investigator
Member: Executive Committee, Endpoints Subcommittee, Ancillary Subcommittee

5R01HL133618 (B. Davis, PI) $256,725.00 2016-2020
Ancillary to ALLHAT - Sustained Blood Pressure Control and Progression of Multimorbidity in ALLHAT NHLBI R01 Subcontract from Duke University/NIH. 2016-2020.
Role: Co-Investigator

1R43HL140624 (B. Davis, PI) $27,000.00 05/2018-04/2019
"HEART: Adding Memory to Reason"
Optima Integrated Health, Inc. / NIH
Role: Co-Investigator

0160100 (B. Davis, PI) Beth Israel Deaconess $15,000.00 2018
"Improved Characteristics of Postural Blood Pressure Change in Older Adults"
Role: Co-Investigator

N0023199 (B. Davis, PI) University of Tasmania $25,000.00 2018
"Ten-year legacy effects of baseline blood pressure 'treatment naivety' in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial"
Role: Co-Investigator

HHSN268201100036C NIH (NHLBI) $101,876,365.00 (1993-2011) $5,000,000 (2012-2016)
"Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial" (ALLHAT)-Phase3: Continuation and Outreach - A clinical trial in 623 centers to compare the effectiveness of four antihypertensive agents in reducing the incidence of coronary heart disease in 42,418 patients 55 years and older with diastolic and/or systolic hypertension. A second nested clinical trial will test the effectiveness of an HMG-CoA reductase inhibitor in reducing the incidence of all-cause mortality in 10,362 of these patients. NHLBI Contract. 1993-2011. ($101,876,365); Phase 3: Continuation and Outreach - 2011-2016 ($5,000,000).
Role: Co-Investigator, Events Monitor, Assistant Project Manager
Member: Executive Committee, Editorial Subcommittee, Endpoints Subcommittee, Dissemination Subcommittee
NHLBI, (B. Davis, PI Coordinating Center $3,721,028 2004-2007
"Improving Blood Pressure in the Community: A Joint Project of the National High Blood Pressure Education Program and Antihypertensive and Lipid Lowering Heart Attack Trial Dissemination Plan" – A dissemination project of ALLHAT,

000418799-002 NIH (NHLBI) (B. Davis, PI Coordinating Center) $274,815 2012-2015
Ancillary to ALLHAT - Visit to Visit Variability of Blood Pressure and CVD and Renal Outcomes. NHLBI R01 (Subcontract from University of Alabama, Birmingham).
Role: Co-Investigator

NHLBI DHHS 5R01HL095511-02 (B. Davis, PI Data Coordinating Center) $3,650,014.00 2010-2015
"Trans-Cranial Doppler (TCD) With Transfusions Changing to Hydroxyurea" (TWiTCH) --: A Phase III randomized clinical trial to compare standard therapy (erythrocyte transfusions) with alternative therapy (hydroxyurea) for the maintenance of lowered TCD velocities in pediatric subjects with sickle cell anemia and abnormal pre-treatment TCD velocities.
Role: Co-Investigator
Member: Operations Subcommittee; TCD Monitoring Group; Outcomes/Safety Group

UO1- HL-87318-01, NIH (NHLBI) Data Coordinating Center (L. Moyé, PI/B. Davis, PI) $17,882,096.00 2006-02/2012

"Cardiovascular Cell Therapy Research Network (CCTRN)" (NHLBI) A network of clinical centers and a coordinating center to conduct phase I and II collaborative trials of emerging cell based treatments of cardiovascular disease.
Role: Co-Investigator
Member: Executive Committee, Endpoints Subcommittee, Regulatory Subcommittee, Ancillary Subcommittee

"Cholesterol and Recurrent Events Trial (CARE)" (L. Moyé, B. Davis Co-PIs Coordinating Center) A clinical trial in 80 centers to test the effectiveness of pravastatin in reducing cardiovascular events in 4000 post-myocardial infarction patients. Bristol-Myers-Squibb, Inc. 1988-2003. $4,468,747.00 1990-1999
Role: Assistant Project Manager
Member: Endpoints Subcommittee, Operations Subcommittee

(L. Moyé, PI Coordinating Center) "Survival and Ventricular Enlargement--The Captopril Study" (SAVE)--A clinical trial in 40 centers to test the effectiveness of captopril in reducing total mortality and/or ventricular enlargement in 2231 post-myocardial infarction patients. Bristol-Myers-Squibb, Inc. 1986-1994.
Role: Graduate Assistant

GRANTS SUBMITTED, Response Pending:
Transplantation Statistical and Clinical Coordinating Center (T-SCCC) 05/01/2023 - 04/30/2028
National Institute of Allergy & Infectious Diseases/NIH/DHHS (NIAID)
Faculty Role Co-Investigator
Total Direct Costs $23,303,350.00/Total Indirect Costs $12,748,893.00

GRANTS/CONTRACTS (NOT FUNDED):
Cardiovascular Biorepository and Resource Center for Type 1 Diabetes 07/01/2022 - 06/30/2027
Texas Heart Institute (THI)/National Institutes of Health/DHHS (NIH)
Role: Co-Investigator
Total Direct Costs $2,038,259.00/Total Indirect Costs $1,124,625.00

LAI NIDDK T1D 12/01/2022 - 11/30/2027
National Institute of Diabetes & Digestive & Kidney Diseases/NIH/DHHS (NIDDK)
Role: Co-Investigator
Total Direct Costs: $6,180,705.00/ Total Indirect Costs $1,813,407.00

Sustained blood pressure control and progression of multimorbidity 09/01/2021 - 08/31/2025
Duke University (DUKEU)/National Institutes of Health/DHHS (NIH)
Role: Co-Investigator
Total Direct Costs $191,584.00/Total Indirect Costs $107,287.00

Electrophysiological Substrate of Arrhythmias: ECGome consortium 09/01/2021 - 08/31/2025
Oregon Health and Science University (OHSU)/National Institutes of Health/DHHS (NIH)
Role Co-Investigator
Total Direct Costs $299,048.00/Total Indirect Costs $167,467.00

"Novel Initiative toward a Treatment Consensus for Hydroxyurea (NiTCH) 2021 - 2025
UG3/UH3: National Heart, Lung and Blood Institute (NIH) (B Davis, PI Data Coordinating Center)
Role: Co-Investigator
Proposed length of study: 5 years
Submitted 10/2018, Resubmitted 06/2020
Total Direct Costs $2,782,973.00/Total Indirect Costs $1,546,368.00

"Blood Pressure Control and Antihypertensive in ALLHAT Trial Participants" 2020-2021
NIH
Role: Co-Investigator

Total Direct Costs $182,175.00/Total Indirect Costs $101,411.00

Intravenous administration of umbiliCAl cord mesenchymal sTrOmal cells in ischemic cardiomyopathy (CATO II) 2020-2021
University of Louisville / NIH
Role: Co-Investigator
Total Direct Costs $1,390,936.00/Total Indirect Costs $531,704.00

Electrophysiological Substrate of Arrhythmias: ECGome consortium (NIH) 2019-2023
Role: Co-Investigator
Total Direct Costs $280,000.00/Total Indirect Costs $151,200.00

Tight Blood Pressure Control and Cardiovascular Outcomes in Hypertensive Patients - Resubmission ALLHAT IV NIH 2019-2023
Role: Co-Investigator
Total Direct Costs $1,112,120.00/Total Indirect Costs $600,543.00

Subgroup Identification in ALLHAT (NIH) 2018-2022
Role: Co-Investigator
Total Direct Costs $1,600,360.00/Total Indirect Costs $864,196.00

ALLHAT Sudden Cardiac Death Study (NIH) OHSU / NIH 2018-2022
Faculty Role Co-Investigator
Total Direct Costs $425,804.00/Total Indirect Costs $229,936.00

Tight Blood Pressure Control and Cardiovascular Outcomes in Hypertensive Patients (NIH) 2018-2022
Faculty Role Co-Investigator
Total Direct Costs $1,832,412.00/Total Indirect Costs $989,503.00

Coordinating Center for "Prevention of Cardiovascular Disease in Diabetic Patients" (PCDD), now known as the ACCORD trial. NHLBI. 1999-2009.
($37,562,893).

Coordinating Center for "Hispanic Health Studies Network", now known as the Hispanic Community Health Study. NHLBI. 2006-2012. ($34,382,000).

Program Project Grant – Biomarkers & Genes & Outcomes & Treatment – A project to utilizing the resources of ALLHAT to assess what are the biomarker, genetic, and clinical factors associated with clinical outcomes of hypertension and are these associations modified by type of treatment? NHLBI. 2010-2015 ($8,821,388).

Coordinating Center Study Ancillary to ALLHAT- Long-term Outcomes in Older Patients with CKD. NIDDK (Subcontract from Case Western Reserve University). 2012-2016 ($459,673).

New Analyses for the ALLHAT. NHLBI. 2012-2016. A grant to continue the work of the ALLHAT Steering Committee and investigators for an additional 5 years. ($3,800,000)

Precision Medicine Initiative (PMI) Enrollment Center. The national PMI cohort will ultimately consist of more than one million individuals who have provided broad consent to participate in a long-term longitudinal research study to identify and understand the factors (genetic, environmental and socio-economic) contributing to individual health and disease. The University of Texas Health Science Center (UTHealth) and Baylor College of Medicine (BCM) partnered to annually recruit from an integrated HPO network more than 35,000 ethnically and economically diverse individuals per year (10,000 in the first year) into the national PMI cohort. NIH. 2016-2021. ($41,000,000).

Precision Medicine Initiative (PMI) Enrollment Center. Resubmission. NIH. 2016-2017. ($5,500,000).

Environmental Influences on Child Health Outcomes (ECHO) Coordinating Center. The overall goal of the ECHO program is to investigate the effect of prenatal, perinatal and postnatal environmental exposures on pediatric health outcomes with high public health impact. To achieve this objective, three institutions, University of Texas Health Science Center at Houston (UTHealth), Baylor College of Medicine (BCOM), and Rice University, located in the world's largest medical complex—Texas Medical Center (TMC), joined together to establish the ECHO Coordinating Center. 2016-2023. ($103,000,000).

PUBLICATIONS:

Cholesterol Treatment Trialists' (CTT) Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024 May;12(5):306-319. Epub 2024 Mar 27. PMID: 38554713 PMCID: 7615958

Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B, Armitage J, Baigent C, Barnes E, Blackwell L, Collins R, Davies K, Emberson J, Fulcher J, Halls H, Herrington W, Holland L, Keech A, Kirby A, Mihaylova B, O'Connell R, Preiss D, Reith C, Simes J, Wilson K, Blazing M, Braunwald E, de Lemos J, Murphy S, Pedersen T, Pfeffer M, White H, Wiviott S, Clearfield M, Downs J, Gotto Jr A, Weis S, Fellström B, Holdaas H, Jardine A,, Gordon D, Davis B, Furberg F, Grimm R, Pressel S, Probstfield J, Rahman M, **Simpson L**, Koren M, Dahlöf B, Gupta A, Poulter N, Sever P, Wedel H, Knopp R, Cobbe S, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Betteridge DJ, Colhoun H, Durrington P, Fuller J, Hitman G, Neil A, Braunwald E, Davis B, Hawkins CM, Moyé L, Pfeffer M, Sacks F, Kjekshus J, Wedel H, Wikstrand J, Wanner JC, Krane V, Grazia Franzosi M, Latini R, Lucci D, Maggioni A, Marchioli R, Nicolis E, Tavazzi E, Tognoni G, Bosch J, Lonn E, Yusuf S, Armitage J, Bowman L, Collins R, Keech A, Landray M, Parish S, Peto R, Sleight P, Kastelein J, Pedersen T, Glynn R, Gotto Jr A, Kastelein J, Koenig W, MacFadyen J, Ridker P, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Simes J, White H, Serruys P, Knatterud G, Blauw G, Cobbe S, Ford I, Macfarlane P, Packard C, Sattar N, Shepherd J, Trompet S, Braunwald E, Cannon C, Murphy S, Collins R, Armitage J, Bowman L, Bulbulia R, Haynes R, Parish S, Peto R, Sleight P, Amarenco P, Welch KM, Kjekshus J, Pedersen T, Wilhelmsen L, Barter P, Gotto Jr A, LaRosa J, Kastelein J, Shepherd J, Cobbe S, Ford I, Kean S, Macfarlane P, Packard C, Roberston M, Sattar N, Shepherd J, Young R, Arashi H, Clarke R, Flather M, Goto S, Goldbourt U, Hopewell J, Hovingh GK, Kitas G, Newman C, Sabatine M,, Smeeth L, Tobert J, Varigos J, Yamamguchi J. Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model. Br J Gen Pract. 2024 Feb 29;74(740):e189-e198. doi: 10.3399/BJGP.2023.0198. Print 2024 Mar. PMID: 38373851 PMCID: 0904120

Yamal JM, Martinez J, Osani MC, Du XL, **Simpson LM**, Davis BR. Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 Dec 1;6(12):e2344998. doi: 10.1001/jamanetworkopen.2023.44998. PMID: 38048133 PMCID:10696481

Du XL, Martinez J, Yamal JM, **Simpson LM**, Davis BR. The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT-Medicare linked data. Front Cardiovasc Med. 2023 Nov 17;10:1272385. doi: 10.3389/fcvm.2023.1272385. eCollection 2023. PMID: 38045916 PMCID: 10691487

Cholesterol Treatment Trialists' Collaboration. Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. Clin Trials. 2022 Dec; 19(6):593-604. PMCID: 7613840

Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022 Sep 10;400(10355):832-845. PMCID: 7613583

Du XL, **Simpson LM**, Osani MC, Yamal JM, Davis BR. Risk of Developing Alzheimer's Disease and Related Dementias in ALLHAT Trial Participants Receiving Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker with 18 Years of Follow-Up. J Alzheimers Dis Parkinsonism. 2022;12(3):541. Epub 2022 Apr 22. PMCID: 9095428

Du XL, **Simpson LM**, Tandy BC, Bettencourt J, Davis BR. Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended. Int J Hypertens. 2021 Dec 9;2021:2261144. eCollection 2021. PMCID: 8677412

Du XL, **Simpson LM**, Tandy BC, Bettencourt JL, Davis BR. Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker. PLoS One. 2021 Nov 18;16(11 eCollection 2021. PMCID: 8601451

Bowling CB, Sloane R, Pieper C, Luciano A, Davis BR, **Simpson LM**, Einhorn PT, Oparil S, Muntner P. Sustained SBP control and long-term nursing home admission among Medicare beneficiaries. J Hypertens. 2021 Nov 1;39(11):2258-2264. PMCID: 9194789

Bowling CB, Sloane R, Pieper C, Luciano A, Davis BR, **Simpson LM**, Einhorn PT, Oparil S, Muntner P. Association of Sustained Blood Pressure Control with Lower Risk for High-Cost Multimorbidities Among Medicare Beneficiaries in ALLHAT. J Gen Intern Med. 2021 Aug;36(8):2221-2229. PMCID: 8342657

Bolli R, Mitrani RD, Hare JM, Pepine CJ, Perin EC, Willerson JT, Traverse JH, Henry TD, Yang PC, Murphy MP, March KL, Schulman IH, Ikram S, Lee DP, O'Brien C, Lima JA, Ostovaneh MR, Ambale-Venkatesh B, Lewis G, Khan A, Bacallao K, Valasaki K, Longsomboon B, Gee AP, Richman S, Taylor DA, Lai D, Sayre SL, Bettencourt J, Vojvodic RW, Cohen ML, **Simpson L**, Aguilar D, Loghin C, Moyé L, Ebert RF, Davis BR, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail. 2021 Apr;23(4):661-674. PMCID: 8357352

Bolli R, Perin EC, Willerson JT, Yang PC, Traverse JH, Henry TD, Pepine CJ, Mitrani RD, Hare JM, Murphy MP, March KL, Ikram S, Lee DP, O'Brien C, Durand JB, Miller K, Lima JA, Ostovaneh MR, Ambale-Venkatesh B, Gee AP, Richman S, Taylor DA, Sayre SL, Bettencourt J, Vojvodic RW, Cohen ML, **Simpson LM**, Lai D, Aguilar D, Loghin C, Moyé L, Ebert RF, Davis BR, Simari RD; for the Cardiovascular Cell Therapy Research Network (CCTRN). J Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial. ACC: Cardiology. 2020 Nov;2(4):581-595. PMCID: 7781291

Bowling CB, Sloane R, Pieper C, Luciano A, Davis BR, **Simpson LM**, Einhorn PT, Oparil S, Muntner P. Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults. J Am Geriatr Soc. . 2020 Sep;68(9):2059-2066. PMCID: 7718414

Juraschek SP, **Simpson LM**, Davis BR, Shmerling RH, Beach JL, Ishak A, Mukamal KJ. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Hypertens. 2020 May;38(5):954-960. PMCID: 7244334

Ho CLB, Sanders S, Breslin M, Doust J, Reid CM, Davis BR, **Simpson LM**, Brouwers FP, Nelson MR. Legacy effect of delayed blood pressure lowering drug treatment in middle-aged adults with mildly elevated blood pressure: systematic review and meta-analysis. J Hum Hypertens. 2020 Apr;34(4):261-270. PMID: 32152453 No NIH Funding.

Ho CLB, Sanders S, Breslin M, Doust J, Reid CM, Davis BR, **Simpson LM**, Brouwers FP, de Boer RA, Nelson MR. Lack of a significant legacy effect of baseline blood pressure 'treatment naivety' on all-cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Hypertens. 2020 Mar;38(3):519-526. PMID: 31584517 No NIH Funding.

Juraschek SP, **Simpson LM**, Davis BR, Beach JL, Ishak A, Mukamal KJ. Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial. Hypertension. 2019 Oct;74(4):1033-1040. PMCID: 6739183

Bowling CB, Davis B, Luciano A, **Simpson L**, Sloane R, Pieper C, Einhorn P, Oparil S, Muntner P. Sustained blood pressure control and coronary heart disease, stroke, heart failure and mortality: An observational analysis of ALLHAT. J Clinical Hypertens. 2019 Apr;21(4):451-459. PMCID: 6532783

Pennells L, Kaptoge S, Wood A, Sweeting M, Zhao X, White I, Burgess S, Willeit P, Bolton T, Moons KGM, van der Schouw YT, Selmer R, Khaw KT, Gudnason V, Assmann G, Amouyel P, Salomaa V, Kivimaki M, Nordestgaard BG, Blaha MJ, Kuller LH, Brenner H, Gillum RF, Meisinger C, Ford I, Knuiman MW, Rosengren A, Lawlor DA, Völzke H, Cooper C, Marín Ibañez A, Casiglia E, Kauhanen J, Cooper JA, Rodriguez B, Sundström J, Barrett-Connor E, Dankner R, Nietert PJ, Davidson KW, Wallace RB, Blazer DG, Björkelund C, Donfrancesco C, Krumholz HM, Nissinen A, Davis BR, Coady S, Whincup PH, Jørgensen T, Ducimetiere P, Trevisan M, Engström G, Crespo CJ, Meade TW, Visser M, Kromhout D, Kiechl S, Daimon M, Price JF, Gómez de la Cámara A, Wouter Jukema J, Lamarche B, Onat A, Simons LA, Kavousi M, Ben-Shlomo Y, Gallacher J, Dekker JM, Arima H, Shara N, Tipping RW, Roussel R, Brunner EJ, Koenig W, Sakurai M, Pavlovic J, Gansevoort RT, Nagel D, Goldbourt U, Barr ELM, Palmieri L, Njølstad I, Sato S, Verschuren WM, Varghese CV, Graham I, Onuma O, Greenland P, Woodward M, Ezzati M, Psaty BM, Sattar N, Jackson R, Ridker PM, Cook NR, D'Agostino RB, Thompson SG, Danesh J, Di Angelantonio E; Emerging Risk Factors Collaboration. Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. Eur Heart J. 2019 Feb 14;40(7):621-631. PMCID: 6374687

Haywood LJ, Davis BR, Piller LB, **Simpson LM**, Ghosh A, Einhorn PT, Ford CE, Probstfield JL, Soliman EZ, Wright JT, ALLHAT Collaborative Research Group. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. J National Med Association. 2018 Aug;110(4):343-351. Epub 2017 Jul 24. PMCID: 6108439.

Dewland TA, Soliman EZ, Yamal JM, Davis BR, Alonso A, Albert CM, **Simpson LM**, Haywood LJ, Marcus GM. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Circ Arrhythm Electrophysiol. 2017 Dec;10(12). PMCID: 5728652

Haywood LJ, Davis BR, Piller LB, Cushman WC, Cutler JA, Ford CE, **Simpson LM**, Ghosh A, Soliman EZ, Wright JT, ALLHAT Collaborative Research Group. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. J National Med Association 2017 Autumn;109(3):172-181. PMCID: 5635839

Bang CN, Soliman EZ, **Simpson LM**, Davis BR, Devereux RB, Okin PM; and for the ALLHAT Collaborative Research Group. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. Am J Hypertens. 2017 Sep 30 (9):914-922. PMCID: 5861536

Alvarez O, Nottage K, **Simpson LM**, Wood J, Davis BR, Fuh B, Sarnaik S, Aygun B, Helton K, Ware RE. Kidney Function of Transfused Children with Sickle Cell Anemia: Baseline Data from the TWiTCH Study with Comparison to Non-Transfused Cohorts. Am J Hematol. 2017 Jul 25. PMCID: 5745054.

Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC, Leeper NJ, Dalman RL, Alexander J, Henry TD, Traverse JH, Pepine CJ, Anderson RD, Berceli S, Willerson JT, Muthupillai R, Gahremanpour A, Raveendran G, Velasquez O, Hare JM, Hernandez Schulman I, Kasi VS, Hiatt WR, Ambale-Venkatesh B, Lima JA, Taylor DA, Resende M, Gee AP, Durett AG, Bloom J, Richman S, G'Sell P, Williams S, Khan F, Gyang Ross E, Santoso MR, Goldman J, Leach D, Handberg E, Cheong B, Piece N, DiFede D, Bruhn-Ding B, Caldwell E, Bettencourt J, Lai D, Piller L, **Simpson L**, Cohen M, Sayre SL, Vojvodic RW, Moyé L, Ebert RF, Simari RD, Hirsch AT; Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery

Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). Circulation. 2017 Apr 11;135(15):1417-1428. Epub 2017 Feb 16. PMCID: 5388585

Chen DP, Davis BR, **Simpson LM**, Cushman WC, Cutler JA, Dobre M, Ford CE, Louis GT, Muntner P, Oparil S, Piller LB, Pressel SL, Sarnak MJ, Whelton PK, Wright JT, Rahman M. Association between chronic kidney disease and cancer mortality: A report from the ALLHAT. Clin Nephrol. Clin Nephrol. 2017 Jan;87 (2017)(1):11-20. PMID: 27900942

Kronish IM, Lynch AI, Oparil S, Whittle J, Davis BR, **Simpson LM**, Krousel-Wood M, Cushman WC, Chang TI, Muntner P. The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 2016 Jul;68(1):39-45. PMCID: 4900942

Whittle J, Lynch AI, Tanner RM, **Simpson LM**, Davis BR, Rahman M, Whelton PK, Oparil S, Muntner P. Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. Clin J Am Soc Nephrol. 2016 Mar 7;11(3):471-80. PMCID: 4791814

Muntner P, Whittle J, Lynch AI, Colantonio LD, **Simpson LM**, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S. Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med. 2015;163(5):329-338. PMCID: 5021508.

Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, **Simpson LM**, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J. 2015 Jun 21;36(24):1536-46. PMCID: 4769322

White IR, Rapsomaniki E; Emerging Risk Factors Collaboration. Covariate-adjusted measures of discrimination for survival data. Biom J. 2015 Jul;57(4):592-613. Epub 2014 Dec 20. PMCID: 4666552

Muntner P, Levitan EB, Lynch AI, **Simpson LM**, Whittle J, Davis BR, Kostis JB, Whelton PK, Oparil S. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens. 2014 May;16(5):323-30. PMCID: 4141643

Piller LB, **Simpson LM**, Baraniuk S, Habib GB, Rahman M, Basile JN, Dart RA, Ellsworth AJ, Fendley H, Probstfield JL, Whelton PK, Davis BR; ALLHAT Collaborative Research Group. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med. 2014 Nov;29(11):1475-83. PMCID: 4238201

Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, Ridker PM, Barr EL, Khaw KT, Psaty BM, Brenner H, Balkau B, Dekker JM, Lawlor DA, Daimon M, Willeit J, Njølstad I, Nissinen A, Brunner EJ, Kuller LH, Price JF, Sundström J, Knuiman MW, Feskens EJ, Verschuren WM, Wald N, Bakker SJ, Whincup PH, Ford I, Goldbourt U, Gómez-de-la-Cámara A, Gallacher J, Simons LA, Rosengren A, Sutherland SE, Björkelund C, Blazer DG, Wassertheil-Smoller S, Onat A, Marín Ibañez A, Casiglia E, Jukema JW, **Simpson LM**, Giampaoli S, Nordestgaard BG, Selmer R, Wennberg P, Kauhanen J, Salonen JT, Dankner R, Barrett-Connor E, Kavousi M, Gudnason V, Evans D, Wallace RB, Cushman M, D'Agostino RB Sr, Umans JG, Kiyohara Y, Nakagawa H, Sato S, Gillum RF, Folsom AR, van der Schouw YT, Moons KG, Griffin SJ, Sattar N, Wareham NJ, Selvin E, Thompson SG, Danesh J. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014 Mar 26;311(12):1225-33. PMCID: 4386007

Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, **Simpson LM**, Stokes JD, Wiegmann TB, Williamson JD; ALLHAT Collaborative Research Group. Long-Term Follow-Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens. 2013 Aug;15(8):542-54. PMCID: 4559328

Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, **Simpson LM**, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012 Dec 12;308(22):2380-2389. PMCID: 3652242.

Emerging Risk Factors Collaboration. Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. Int J Epidemiol. 2012 Oct;41(5):1419-1433. PMCID: 3465767

Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, **Simpson LM**, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; for the Cardiovascular Cell Therapy Research Network (CCTRN). Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure: The FOCUS-CCTRN Trial. JAMA. 2012;307(16):1717-1726. PMCID: 3600947.

Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, Wright JT Jr, Barzilay JI, Brown CD, Colon PJ Sr, Fine LJ, Grimm RH Jr, Gupta AK, Baimbridge C, Haywood LJ, Henriquez MA, Ilamaythi E, Oparil S, Preston R; ALLHAT Collaborative Research Group. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol. 2012 Jun;7(6):989-1002. PMCID: 3362309.

Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012 May;59(5):926-933. PMCID: 3373273.

Rapsomaniki E, White IR, Wood AM, Thompson SG; Emerging Risk Factors Collaboration. A framework for quantifying net benefits of alternative prognostic models. Stat Med. 2012 Jan 30;31(2):114-30. PMCID: 3496857

Cushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Ford CE, Oparil S, Probstfield JL, Whelton PK, Wright JT, Alderman MH, Basile JN, Black HR, Grimm RH, Hamilton BP, Haywood LJ, Ong ST, Piller LB, **Simpson LM,** Stanford C, Weiss RJ; for the ALLHAT Collaborative Research Group. Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial. J Clin Hypertens. 2012;14:20-31. PMCID: 3261592

Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, **Simpson LM**, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C,

Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011 Nov 16;306(19):2110-2119. PMCID: 2929864

Piller LB, Baraniuk S, **Simpson LM**, Cushman WC, Massie BM, Einhorn PT, Oparil S, Ford CE, Graumlich JF, Dart RA, Parish DC, Retta TM, Cuyjet AB, Jafri SZ, Furberg CD, Saklayen MG, Thadani U, Probstfield JL, Davis BR; ALLHAT Collaborative Research Group. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011 Oct 25;124(17):1811-1818. PMCID: 3217334

Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011 Mar 3;364(9):829-841. PMCID: 4109980

Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DXM, **Simpson LM**, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari R,D for the Cardiovascular Cell Therapy Research Network (CCTRN). LateTIME: A Phase-II, Randomized, Double-Blinded, Placebo-Controlled Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells 2 to 3 Weeks after Acute Myocardial Infarction. Tex Heart Inst J 2010;37:412-420. PMCID: 2929864

Thompson S, Kaptoge S, White I, Wood A, Perry P, Danesh J; Emerging Risk Factors Collaboration. Collaborators (245): Tipping RW, Ford CE, **Simpson LM**, Walldius G, et al. Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. Int J Epidemiol. 2010;39:1345-1359. PMCID: 2972437

Margolis KL, Dunn K, **Simpson LM**, Ford CE, Williamson JD, Gordon DJ, Einhorn PT, Probstfield JL, for the ALLHAT Collaborative Research Group. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin vs. Usual care: The Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial (ALLHAT-LLT). Am Heart J. 2009;158:948-955. PMCID: 2904958

Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson G, Einhorn PT, Graumlich JF, Piller LB, Pressel S, Roccella EJ, **Simpson L**, Whelton PK, Williard A. Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. Clinical Trials. 2009;6:329-343. PMCID: 2897824

Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry P, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J, Tipping R, Ford CE, **Simpson LM**, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA. 2009;302:412-423. PMCID: 3272390

Davis BR, Kostis JB, **Simpson LM**, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S, for the ALLHAT Collaborative Research Group. Heart failure with preserved and reduced left ventricular ejection fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 2008;118:2259-2267. PMCID: 2775475

Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, **Simpson LM**, Levy D, Nwachuku CE, Black HR; ALLHAT Collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J. 2007 Jan;153(1):42-53. PMID: 17174636

Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, **Simpson LM**, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep;48(3):374-84. PMID: 16864749

ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42(3):239-246. PMID: 12925554

ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-2997. PMID: 12479763

ALLHAT Officers and Coordinators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care - The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002;288(23):2998-3007. PMID: 12479764

Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, **Simpson LM**, Nwachuku C, Furberg CD, for the ALLHAT Collaborative Research Group. Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Controlled Clinical Trials 2001;22(1):29-41. PMID: 11165421

Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, **Simpson LM,** Braunwald E, for the CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin - The Cholesterol and Recurrent Events (CARE) study. Circulation 1999;99(2):216-223. PMID: 9892586

ACCEPTED:

RESUBMITTED:

LETTERS:
Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, **Simpson LM**, Stokes JD, Wiegmann TB, Williamson JD. Author response to lipid-lowering in African Americans in ALLHAT-optimism bias? J Clin Hypertens. 2013 Dec;15(12):941.

Davis BR, **Simpson LM**, Ford CE, Kostis JB, Black HR, Cushman WC, Einhorn PT, Farber MA, Levy D, Massie BM, Nawaz S, For the ALLHAT Collaborative Research Group. Response to Letter Regarding Article, "Heart Failure with Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial." Circulation. 2009;120;e32.

POSTERS AND ABSTRACTS
Dewland TA, Soliman EZ, Davis BR, Yamal JM, Alonso A, Alpert CM, **Simpson LM**, Marcus GM. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Follow Up from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Heart Rhythm 2015;12(5)S:467-467.

Bang CN, Soliman E, **Simpson LM**, Davis B, Devereux R, Okin P. Electrocardiographic left ventricular hypertrophy predicts cardiovascular morbidity and mortality in hypertensive patients: the ALLHAT Study. J Am Coll Cardiol 2015;Mar 65(S):A1460-A1460.

Muntner P, Whittle J, Lynch AI, **Simpson LM**, Einhorn P, Levitan EB, Whelton PK, Cushman WC, Louis G, Davis BR, Oparil S. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure and mortality: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Society Hypertens 2014;8(4):e13-e14.

Chen D, Pressel S, Davis B, Dobre M, Muntner P, Sarnak M, **Simpson L**, Whelton P, Wright JT, Rahman M. Association between lower estimated glomerular filtration rate (GFR) and incident cancer: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2014;63(5):A38-A38.

Pressel S, Davis BR, Ford C, Piller LB, **Simpson LM**, Baraniuk S, for the ALLHAT Collaborative Research Group. The utility of post-trial follow-up of participants – the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial experience. Clinical Trials 2010;7:468-468.

Piller LB, **Simpson LM**, Habib GB, Rahman M, Basile J, Courtney D, Dart R, Einhorn P, Ellsworth A, Fendley H, Leenen FHH, Morrison D, Whelton PK. Major secondary outcomes in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2008;10(5SA):125.

Davis BR, **Simpson LM**, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S. Heart failure with preserved and impaired left ventricular systolic function in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 2006;114(18S):571.

Habib G, Basile J, Courtney D, Dart R, Einhorn P, Ellsworth A, Fendley H, Leenen F, Morrison D, Plller L, Rahman M, **Simpson L**, Whelton P, for the ALLHAT Collaborative Research Group. Are ACE-inhibitors or calcium channel blockers superior to diuretics in preventing angina or peripheral arterial disease or the need for revascularization? Insights from ALLHAT. J Hypertens 2006;24(4)S90.

Leenen F, Nwachuku C, Cushman W, Black H, **Simpson L**, Davis B, for the ALLHAT Collaborative Research Group. Outcomes in high risk hypertensives randomized to calcium channel blocker versus angiotensin converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Hypertens 2005;23(S2):S113.

Leenen F, Nwachuku C, Cushman W, Black H, **Simpson L**, Davis B, for the ALLHAT Collaborative Research Group. Cardiovascular outcomes in hypertensives with coronary artery disease randomized to amlodipine versus lisinopril in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Hypertens 2005;23(S2):S21-S22.

Leenen F, Nwachuku C, Cushman W, Black H, **Simpson L,** Davis B. Outcomes in high risk hypertensives randomized to CCB vs ACE inhibitor in ALLHAT. Am J Hypertens 2005;18(5S):7A.

Einhorn PT, Davis BR, Piller LB, **Simpson LM,** Kostis JB, Levy D, Massie BM, Nwachuku C, Black HR, Cushman WC. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure (HF) validation study: Clinical presentation of hospitalized HF events and subsequent mortality rates. Circulation 2004;110(17S):731.

Einhorn P, Davis B, Piller L, deLeon B, **Simpson L,** Kostis J, Levy D, Massie B, Nwachuku C, Black H, Cushman W, for the ALLHAT Collaborative Research Group. Review of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT heart failure validation study. Circulation 2003;108(17S):399-400.

deLeon B, Piller L, Pressel S, **Simpson L**, Bettencourt J, Davis B. Validation of secondary outcomes - A case study from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Control Clin Trials 2003;24(S3):186S.

Simpson L, Pressel S, Piller L, Bettencourt J, DeLeon B, Davis B. Ascertainment of vital status using outside databases in ALLHAT. Controlled Clin Trials 2002;23(S1):76S.

Piller L, **Simpson L,** Davis B, Pressel S, DeLeon B. The review of Event Reports in ALLHAT. Control Clin Trials 2002;23(S1):77S.

Brown L, Sestier F, Nash DT, Cuddy TE, Wilt TJ, Howard J, Moye LA, **Simpson L**, Sacks F. Coronary risk factors predict recurrent coronary events after myocardial infarction. Circulation 1998;98(17S)323.

Papademetriou V, Nash D, Narayan P, Davis B, **Simpson L**, Marais G, Rouleau J, Sacks F. Influence of calcium channel blocker therapy on cardiovascular outcomes in the Cholesterol And Recurrent Events (CARE) trial. JACC 1998;31(2A):407A.

Plehn JF, Rouleau JL, Pfeffer MA, Davis BR, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford JD, **Simpson LM**, Braunwald E, Sacks FM, for the CARE Investigators. Reduction of stroke incidence following myocardial infarction with pravastatin: The CARE study. Stroke 1998;29(1):286.